Company Overview of EOS S.p.A.
EOS S.p.A. is engaged in the development of drug product candidates for the treatment of cancer. It is primarily involved in the development of Lucitanib, an oral small-molecule tyrosine kinase inhibitor that is in Phase I/II development to prevent the development of new blood vessels essential for tumor growth and to interfere with tumor growth in certain FGF-dependent malignancies. The company was founded in 2006 and is based in Milan, Italy. As of November 19, 2013, EOS S.p.A. operates as a subsidiary of Clovis Oncology, Inc.
Via Monte di Pietà n.1/A
Milan, MI 20121
Founded in 2006
39 02 87 39 16 08
39 02 87 39 16 17
Key Executives for EOS S.p.A.
EOS S.p.A. Key Developments
Similar Private Companies By Industry
|Siena Biotech S.p.A.||Europe|
|Baxter Manufacturing S.p.A.||Europe|
Recent Private Companies Transactions
November 19, 2013
To contact EOS S.p.A., please visit www.eosmilano.com. Company data is provided by Capital IQ. Please use this form to report any data issues.